Overview Pfizer has faced a significant downtrend since the peak of the pandemic-driven demand for Covid vaccines. However, the negative sentiment surrounding the stock appears to have overshot reality, presenting an opportunity for value-oriented investors. While the company’s stock price has declined substantially, its fundamentals suggest undervaluation. Despite challenges, such as reduced guidance for 2024,Continue reading “Reviving Pfizer: Unveiling Value in a Downtrend”
